AtriCure Prices Public Offering of Common Stock
WEST CHESTER, Ohio -- January 16, 2013
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial fibrillation, or
AF, and systems for the exclusion of the left atrial appendage, today
announced the pricing of its previously announced underwritten public offering
of 3,475,000 shares of its common stock at a public offering price of $7.25
per share. In connection with the offering, AtriCure has also granted the
underwriter a 30-day option to purchase up to an additional 521,250 shares of
common stock to cover over-allotments, if any. Piper Jaffray& Co. is acting
as the sole manager for the offering.
Net proceeds from the sale of the shares after underwriting discounts and
commissions and other offering expenses are expected to be approximately $23.5
million. The offering is subject to customary closing conditions and is
expected to close on Tuesday, January22, 2013.
AtriCure plans to use the net proceeds from the offering for general corporate
purposes and working capital.
The offering was made pursuant to a prospectus supplement to AtriCure’s
prospectus, dated July 20, 2011, filed as part of AtriCure’s effective
$50million shelf registration statement.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
Copies of the preliminary prospectus supplement and accompanying prospectus
relating to these securities may be obtained by contacting Piper Jaffray&
Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
MN 55402 or by telephone at 800-747-3924 or by email at firstname.lastname@example.org.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart, tissue for
the treatment of atrial fibrillation, or AF, and systems for the exclusion of
the left atrial appendage. The Company believes cardiothoracic surgeons are
adopting its ablation products for the treatment of AF during concomitant
open-heart surgical procedures and sole-therapy minimally invasive procedures.
AF affects more than 5.5 million people worldwide and predisposes them to a
five-fold increased risk of stroke. The FDA has not cleared or approved
certain AtriCure products for the treatment of AF or a reduction in the risk
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or developments
that AtriCure expects, believes or anticipates will or may occur in the
future, such as earnings estimates, other predictions of financial
performance, launches by AtriCure of new products and market acceptance of
AtriCure’s products. Forward-looking statements are based on AtriCure’s
experience and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many of
which are beyond AtriCure’s control. These risks and uncertainties include the
rate and degree of market acceptance of AtriCure’s products, AtriCure’s
ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of procedures
utilizing AtriCure’s products, competition from existing and new products and
procedures or AtriCure’s ability to effectively react to other risks and
uncertainties described from time to time in AtriCure’s SEC filings, such as
fluctuation of quarterly financial results, reliance on third party
manufacturers and suppliers, litigation or other proceedings, government
regulation and stock price volatility. AtriCure does not guarantee any
forward-looking statement, and actual results may differ materially from those
projected. AtriCure undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact:
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.